April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Long Term Efficacy of Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions
Author Affiliations & Notes
  • Xining He
    Ophthalmology, Yale University School of Medicine, New Haven, CT
  • Maxwell Elia
    Ophthalmology, Yale University School of Medicine, New Haven, CT
  • Eric Hsieh
    Ophthalmology, Yale University School of Medicine, New Haven, CT
  • Ron A Adelman
    Ophthalmology, Yale University School of Medicine, New Haven, CT
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3918. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xining He, Maxwell Elia, Eric Hsieh, Ron A Adelman; Long Term Efficacy of Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3918.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the long-term effect of Bevacizumab on macular edema secondary to central and branch retinal vein occlusions.

Methods: Retrospective study of 12 consecutive patients with macular edema secondary to retinal vein occlusions with a minimum of 3-years of follow up. Patients were evaluated at baseline using Optical Coherence Tomography (OCT) and Fluorescein Angiography and given intravitreal injections of Bevacizumab. Patients were followed with OCT and further injections were administered on follow up visits if persistent edema was noted (as needed therapy). Patients who received any other concurrent treatment modality were excluded from this study. The primary end points included visual acuity and central macular thickness (CMT) at 3- and 5- years. Statistical analyses were performed with paired T-tests.

Results: A total of 12 patients (mean age 59) were included. All patients had at least 3-years of follow up and 6 patients had 5-years of follow up. There was an improvement in logMAR visual acuity of -0.24 (p=0.02) after 3 years and -0.19 (p=0.47) after 5 years. There was a statistically significant reduction in mean CMT from 374 to 254 microns (difference=120, p=0.001) after 3 years, and from 470 to 304 microns (difference=166, p=0.01) after 5 years.

Conclusions: As needed intravitreal injections of Bevacizumab lead to a significant reduction in macular edema after three years and after five years. Intravitreal injections of Bevacizumab improved visual acuity after three years.

Keywords: 505 edema • 748 vascular endothelial growth factor • 749 vascular occlusion/vascular occlusive disease  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×